The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

被引：23

作者：

Cordoba, I. ^{[1
]}

Gonzalez-Porras, J. R. ^{[1
]}

Such, E. ^{[2
]}

Nomdedeu, B. ^{[3
]}

Luno, E. ^{[4
]}

de Paz, R. ^{[5
]}

Carbonell, F. ^{[6
]}

Vallespi, T. ^{[7
]}

Ardanaz, M. ^{[8
]}

Ramos, F. ^{[9
,10
]}

Marco, V. ^{[11
]}

Bonanad, S. ^{[12
]}

Sanchez-Barba, M. ^{[13
]}

Costa, D. ^{[3
]}

Bernal, T. ^{[4
]}

Sanz, G. F. ^{[2
]}

Canizo, M. C. ^{[1
]}

机构：

[1] Hosp Univ Salamanca, Salamanca 37007, Spain

[2] Hosp Univ La Fe, Valencia, Spain

[3] Hosp Clin Barcelona, Barcelona, Spain

[4] Hosp Univ Cent Asturias, Oviedo, Spain

[5] Hosp Univ La Paz, Madrid, Spain

[6] Hosp Gen Univ, Valencia, Spain

[7] Hosp Valle De Hebron, Barcelona, Spain

[8] Hosp Txagorritxu, Vitoria, Spain

[9] Hosp Leon, Leon, Spain

[10] IBIOMED, Leon, Spain

[11] Hosp Arnau Vilanova, Lleida, Spain

[12] Hosp de La Ribera, Alzira, Spain

[13] CAIBER Invest Unit, Salamanca, Spain

来源：

LEUKEMIA RESEARCH | 2012年 / 36卷 / 03期

关键词：

Myelodysplastic syndrome; Neutropenia; Cytopenia; Prognostic; Survival; COLONY-STIMULATING FACTOR; WORLD-HEALTH-ORGANIZATION; MYELOID NEOPLASMS; ACUTE-LEUKEMIA; PHASE-II; G-CSF; ERYTHROPOIETIN; ANEMIA; INFECTION; CLASSIFICATION;

D O I：

10.1016/j.leukres.2011.10.025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The severity of neutropenia in myelodysplastic syndrome (MDS) has not been completely studied. We analyzed the prognostic significance of severe neutropenia (neutrophils count < 0.5 x 10(9)/L) at diagnosis in 1109 patients with de novo MDS and low/intermediate-1 IPSS included in the Spanish MDS Registry. Severe neutropenia was present at diagnosis in 48 of 1109 (4%). Patients with severe neutropenia were most strongly represented within the groups of refractory cytopenia with multilineage dysplasia (40%) and refractory anemia with excess of blast type 1 (29%). Severe neutropenia had negative effects on the low/intermediate-1 risk group. A significant difference in overall survival was observed between patients with severe neutropenia (28 months) and patients with a neutrophil count higher than 0.5 x 10(9)/L (66 months) (p < 0.0001). Also, severe neutropenia predicted a significantly reduced on leukemia-free survival (p < 0.0001). In the multivariate analysis, severe neutropenia retained its independent prognostic influence on overall survival [HR: 2.19, 95% CI (1.41-3.10), p < 0.0001] and leukemia free survival [HR: 3.51, 95% CI (1.97-6.26), p < 0.0001]. The degree of neutropenia should be considered as additional prognostic factor in low/intermediate-1 IPSS MDS. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：287 / 292

页数：6

共 24 条

[1]

BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[2] QUANTITATIVE RELATIONSHIPS BETWEEN CIRCULATING LEUKOCYTES AND INFECTION IN PATIENTS WITH ACUTE LEUKEMIA [J].

BODEY, GP ;

BUCKLEY, M ;

SATHE, YS ;

FREIREICH, EJ .

ANNALS OF INTERNAL MEDICINE, 1966, 64 (02) :328-+

[3] Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes:: a randomized, controlled trial [J].

Casadevall, N ;

Durieux, P ;

Dubois, S ;

Hemery, F ;

Lepage, E ;

Quarré, MC ;

Damaj, G ;

Giraudier, S ;

Guerci, A ;

Laurent, G ;

Dombret, H ;

Chomienne, C ;

Ribrag, V ;

Stamatoullas, A ;

Marie, JP ;

Vekhoff, A ;

Maloisel, F ;

Navarro, R ;

Dreyfus, F ;

Fenaux, P .

BLOOD, 2004, 104 (02) :321-327

[4] Cause of Death in Patients With Lower-Risk Myelodysplastic Syndrome [J].

Dayyani, Farshid ;

Conley, Anthony P. ;

Strom, Sara S. ;

Stevenson, William ;

Cortes, Jorge E. ;

Borthakur, Gautam ;

Fader, Stefan ;

O'Brien, Susan ;

Pierce, Sherry ;

Kantarjian, Hagop ;

Garcia-Manero, Guillermo .

CANCER, 2010, 116 (09) :2174-2179

[5] A prognostic score for patients with lower risk myelodysplastic syndrome [J].

Garcia-Manero, G. ;

Shan, J. ;

Faderl, S. ;

Cortes, J. ;

Ravandi, F. ;

Borthakur, G. ;

Wierda, W. G. ;

Pierce, S. ;

Estey, E. ;

Liu, J. ;

Huang, X. ;

Kantarjian, H. .

LEUKEMIA, 2008, 22 (03) :538-543

[6] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[7]

GREENBERG P, 1993, BLOOD, V82, P196

[8] Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996) [J].

Greenberg, Peter L. ;

Sun, Zhuoxin ;

Miller, Kenneth B. ;

Bennett, John M. ;

Tallman, Martin S. ;

Dewald, Gordon ;

Paietta, Elisabeth ;

van der Jagt, Richard ;

Houston, Jessie ;

Thomas, Mary L. ;

Cella, David ;

Rowe, Jacob M. .

BLOOD, 2009, 114 (12) :2393-2400

[9] Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin:: Results from a randomized phase II study and long-term follow-up of 71 patients [J].

Hellström-Lindberg, E ;

Ahlgren, T ;

Beguin, Y ;

Carlsson, M ;

Carneskog, J ;

Dahl, IM ;

Dybedal, I ;

Grimfors, G ;

Kanter-Lewensohn, L ;

Linder, O ;

Luthman, M ;

Löfvenberg, E ;

Nilsson-Ehle, H ;

Samuelsson, J ;

Tangen, JM ;

Winqvist, I ;

Öberg, G ;

Österborg, A ;

Öst, Å .

BLOOD, 1998, 92 (01) :68-75

[10] Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF [J].

Jädersten, M ;

Montgomery, SM ;

Dybedal, I ;

Porwit-MacDonald, A ;

Hellström-Lindberg, E .

BLOOD, 2005, 106 (03) :803-811

← 1 2 3 →